Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative

American Journal of Epidemiology

Volumn 150, Issue 10, 1999, Pages 1001-1021

  Fine, Paul E M ^a   Carneiro, Ilona A M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Enterovirus; Immunization programs; Poliomyelitis; Poliovirus vaccine, oral; Vaccines

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

DISEASE TRANSMISSION; VACCINATION; VIRAL DISEASE;

ERADICATION THERAPY; PERSISTENT VIRUS INFECTION; POLIOMYELITIS; POLIOMYELITIS VIRUS; REVIEW; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 0032714330     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009924     Document Type: Review

References (159)

1. World Health Organization. Global eradication of poliomyelitis by the year 2000. Resolution 41.28, agenda item 12, pp 1-3, of the 41st World Health Assembly, Geneva, Switzerland, May 13, 1988.
2. Gelfand HM, LeBlanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg 1957; 65:367-85.
3. Minor PD. The molecular biology of poliovaccines. J Gen Virol 1992;73:3065-77.
4. Dunn G, Begg NT, Cammack N, et al. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol 1990;32: 92-5.
5. Abraham R, Minor P, Dunn G, et al. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 1993;168:1105-9.
6. Fiore L, Pierangeli A, Lombardi F, et al. Antigenic and biochemical characterization of poliovirus type 2 isolated from two cases of paralytic disease. Intervirology 1987;27:196-204.
7. Lipskaya GY, Muzychenko AR, Kutitova OK, et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J Med Virol 1991;35:290-6.
8. Furione M, Guillot S, Otelea D, et al. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 1993;196:199-208.
9. World Health Organization. Primary immunodeficiency diseases: report of a WHO scientific group. Clin Exp Immunol 1997;109(suppl 1):1-28.
10. Wright PF, Hatch MH, Kasselberg AG, et al. Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinaemia. J Pediatr 1977;91:408-12.
11. Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994;11:426-38.
12. MacCallum FO. Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B) 1971;310:72-85.
13. Hara M, Saito Y, Komatsu T, et al. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol 1981;25:905-13.
14. Savilahti E, Klemola T, Carlsson B, et al. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged. J Clin Immunol 1988;8:89-94.
15. Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep 1997;46:641-3.
16. Baumgart KW, Britton WJ, Kemp A, et al. The spectrum of primary immunodeficiency disorders in Australia. J Allergy Clin Immunol 1997;100:415-23.
17. Fasth A. Primary immunodeficiency disorders in Sweden: cases among children, 1974-1979. J Clin Immunol 1982;2: 86-92.
18. Thorsteinsson L, Ogmundsdottir HM, Sigfusson A, et al. The first Icelandic family with X-linked agammaglobulinaemia: studies of genetic markers and immune function. Scand J Immunol 1990;32:273-80.
19. Grumach AS, Duarte AJ, Bellinati-Pires R, et al. Brazilian report on primary immunodeficiencies in children: 166 cases studied over a follow-up time of 15 years. J Clin Immunol 1997;17:340-5.
20. Ion Nedelcu N, Dobrescu A, Strebel PM, et al. Vaccine-associated paralytic poliomyelitis and HIV infection. (Letter). Lancet 1994;343:51-2.
21. Ryder RW, Oxtoby MJ, Mvula M, et al. Safety and immunogenicity of Bacille Calmette-Guerin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 1993;122:697-702.
22. Kitayaporn D, Tansuphaswadikul S, Lohsomboon P, et al. Survival of AIDS patients in the emerging epidemic in Bangkok, Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:77-82.
23. Morgan D, Maude GH, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997;350:245-50.
24. Dunne MT, Ruskin HJ, Mulcahy FM. Survival with AIDS in Ireland. AIDS 1997;11:1281-90.
25. Centers for Disease Control and Prevention. Meeting on "Prolonged excretion of poliovirus in immune deficient persons." Atlanta: CDC, 1997.
26. Sabin AB. Present status of attenuated live-virus poliomyelitis vaccine. JAMA 1956;162:1589-96.
27. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis 1997;175(suppl 1): S286-92.
28. Gelfand HM, Potash L, LeBlanc DR, et al. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. JAMA 1959;170:85/2039-94/2048.
29. Keswick BH, Pickering LK, DuPont HL, et al. Survival and detection of rotaviruses on environmental surfaces in day care centers. Appl Environ Microbiol 1983;46:813-16.
30. Yates MV, Gerba CP, Kelley LM. Virus persistence in groundwater. Appl Environ Microbiol 1985;49:778-81.
31. Hemmes JH, Winkler KC, Kool SM. Virus survival as a seasonal factor in influenza and poliomyelitis. Antonie Van Leeuwenhoek 1962;28:221-3.
32. Hurst CJ, Benton WH, McClellan KA. Thermal and water source effects upon the stability of enteroviruses in surface freshwaters. Can J Microbiol 1989;35:474-80.
33. Yorke JA, Nathanson N, Pianigiani G, et al. Seasonality and the requirements for perpetuation and eradication of viruses in populations. Am J Epidemiol 1979;109:103-23.
34. Fox JP, Hall CE. Poliomyelitis in Louisiana. In: Viruses in families: surveillance of families as a key to epidemiology of virus infections. Littleton, MA: PSG Publishing Company, Inc, 1980:93-151.
35. Tierney JT, Sullivan R, Larkin EP. Persistence of poliovirus 1 in soil and on vegetables grown in soil previously flooded with inoculated sewage sludge or effluent. Appl Environ Microbiol 1977;33:109-13.
36. World Health Organization. Proposed global action plan and timetable for safe handling and minimum laboratory containment of wild polioviruses and potentially infectious materials. Geneva: World Health Organization, 1998. (WHO/EPI/ Gen/98.05).
37. Mulders MN, Reimerink JH, Koopmans MP, et al. Genetic analysis of wild-type poliovirus importation into the Netherlands (1979-1995). J Infect Dis 1997; 176:617-24.
38. Fox JP, Hall CE. Experimental studies with vaccine strains of polioviruses. In: Viruses in families: surveillance of families as a key to epidemiology of virus infections. Littleton, MA: PSG Publishing Company, Inc, 1980:152-95.
39. Fox JP. The spread of vaccine strains of poliovirus in the household and in the community in southern Louisiana. (Abstract). In: Poliomyelitis: papers and discussions presented at the 5th International Poliomyelitis Conference, Copenhagen, Denmark, July 26-28, 1960. Philadelphia: JB Lippincott Co, 1960:24-5.
40. Benyesh-Melnick M, Melnick JL, Ramos Alvarez M. Poliomyelitis infection rate among Mexican children fed attenuated poliovirus vaccines. In: Proceedings of the 1st International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959: 272-85.
41. Benyesh-Melnick M, Melnick JL, Rawlis WE, et al. Studies of the immunogenicity, communicability, and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 1967;86:112-36.
42. Sabin AB, Michaels RH, Spigland I, et al. Community-wide use of oral poliovirus vaccine: effectiveness of the Cincinnati Program. Am J Dis Children 1961;101:546-67.
43. Koprowski H, Plotkin S, Pagano J, et al. Behaviour of attenuated strains of poliomyelitis virus in relation to age, familial spread, and duration of immunity. In: Proceedings of the 1st International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959: 159-71.
44. Horstmann DM, Niederman JC, Riordan JT, et al. The trial use of Sabin's attenuated type 1 poliovirus vaccine in a village in southern Arizona. Am J Hyg 1959;70:169-84.
45. Fox JP. Factors influencing dissemination of wild and vaccine strains of poliovirus in Louisiana. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:531-45.
46. Horstmann DM, Niederman JC, Paul JR. Attenuated type 1 poliovirus vaccine. Its capacity to spread from "vaccinees" within an institutional population. JAMA 1959;170:1-8.
47. Smorodintsev AA, Ilyenko VI, Kurnosova MM, et al. Virological and immunological characteristics of vaccinal infection in children inoculated per os with a live poliomyelitis vaccine made from the Sabin strains. In: Proceedings of the 1st International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959:312-23.
48. Horstmann DM, Paul JR, Godenne-McCrea M, et al. Immunization of preschool children with oral poliovirus vaccine (Sabin). JAMA 1961;178:693-701.
49. Koroleva GA, Zhevandrova VI, Voroshilova MK, et al. Virologic and serologic survey of children in contact with those immunized with live poliovirus vaccine. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961: 584-7.
50. Drosdov SG, Shirman GA, Ashmarina EE, et al. Dynamics of excretion of the three types of vaccine virus in vaccinated children and their contacts. Investigation of properties of virus isolates. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:165-73.
51. Zhevandrova VI, Koroleva GA, Voroshilova MK. The dynamics of vaccine strain excretion in oral immunization with trivalent live poliomyelitis vaccine. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:174-80.
52. Ginter VX, Indulen MK, Kanel IA. Spread of vaccine virus in boarding children's institutions and households during immunization with live poliovirus vaccine. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:588-90.
53. Japan Live Poliovaccine Research Commission. Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children. Jpn J Med Sci Biol 1966;19:277-91.
54. Glezen WP, Lamb GA, Beiden EA, et al. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 1966;83:224-37.
55. Bodian D, Paffenbarger RS. Poliomyelitis infection in households: frequency of viremia and specific antibody response. Am J Epidemiol 1954;60:83-93.
56. Paffenbarger RS, Wilson VO, Bodian D, et al. The spread of poliomyelitis: an analysis of contact during epidemic periods. Am J Hyg 1954;60:63-82.
57. Fox JP, Gelfand HM, LeBlanc DR, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. I. Over-all plan, methods and observations as to patterns of seroimmunity in the study group. Am J Hyg 1957; 65:344-66.
58. Isacson P, Melnick JL, Walton M. Environmental studies of endemic enteric virus infections. II. Poliovirus infections in household units. Am J Hyg 1957;65:29-42.
59. Gelfand HM, LeBlanc DR, Potash L, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg 1959;70:312-27.
60. Wehrel PF, Carbonaro O, Day PA, et al. Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. Pediatrics 1961;27:762-4.
61. Chin TDY, Marine WM, Hall EC, et al. Poliomyelitis in Des Moines, Iowa, 1959. The influence of Salk vaccination on the epidemic pattern and the spread of the virus in the community. Am J Hyg 1961;74:67-94.
62. Marine WM, Chin TDY, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. Am J Hyg 1962;76:173-95.
63. Melnick JL, Benyesh-Melnick M. Problems associated with live poliovirus vaccine and its progeny after multiplication in man. In: Proceedings of the 2nd International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1960:12-27.
64. Voroshilova MK, Lavrova LK, Balayan MS, et al. Investigation of type III poliovirus strains, recovered from live virus vaccinees, in monkey tests and by titrations at 36°C and 40°C. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:227-30.
65. Ghendon YZ, Khesin YE, Marchenko AT. Study of stability of the genetic characters of Sabin attenuated poliomyelitis virus strains. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:456-76.
66. Robinson IA, Sheftel MA, Yurovetskaya AL, et al. Changes in the central nervous system of monkeys inoculated with type in strains isolated from feces of children vaccinated with oral live vaccine. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:231-7.
67. Dane DS, Dick GWA, Briggs M, et al. Vaccination against poliomyelitis with live virus vaccines. 8. Changes in Sabin type I oral vaccine virus after multiplication in the intestinal tract. Br Med J 1961;2:269-71.
68. Dane DS, Dick GWA, Briggs M, et al. Vaccination against poliomyelitis with live virus vaccines. 6. Changes in Sabin type II oral vaccine virus after human passage. Br Med J 1961;2:259-65.
69. Sabin AB. Recent studies and field tests with a live attenuated poliovirus vaccine. In: Proceedings of the 1st International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959:14-33.
70. Oker-Blom N, Strandstrom H, Eriksson AW. A small-scale trial with live poliovirus vaccine in an isolated island community. In: Proceedings of the 1st International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959:580-7.
71. Kew OM, Mulders MN, Lipskaya GY, et al. Molecular epidemiology of polioviruses. Semin Virol 1995;6:401-14.
72. Klyuchareva TE. Changes in the neurotropic properties of attenuated strains of the poliomyelitis virus after lengthy circulation through the susceptible organism of children. In: Smorodintsev AA, ed. Living vaccine against poliomyelitis: a collection of articles from the Virology Department. (In Russian). Leningrad: Works of the Institute of Experimental Medicine, AMS, USSR, 1960.
73. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States (see comments). JAMA 1996;275:1639-45.
74. Aylward RB, Porta D, Fiore L, et al. Unimmunized gypsy populations and implications for the eradication of poliomyelitis in Europe. J Infect Dis 1997;175(suppl 1): S86-8.
75. World Health Organization. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 1997;175(suppl 1):S215-27.
76. Zacek K, Adam E, Adamova V, et al. Mass oral (Sabin) poliomyelitis vaccination: virological and serological surveillance in Czechoslovakia, 1958-9 and 1960. Br Med J 1962;1:1091-8.
77. Domok I, Molnar E, Jancso A, et al. Enterovirus survey in children after mass vaccination with live attenuated polioviruses. Br Med J 1962;1:743-6.
78. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine: effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960;173: 1521-6.
79. Mas Lago P, Louzara C, Beltran J, et al. Circulacion de poliovirus en la poblacion infantil de Cuba. (In Spanish). Bol Oficina Sanit Panam 1979;87:377-88.
80. Ochoa EG, Mas Lago P. Epidemiological surveillance and control of poliomyelitis in the Republic of Cuba. J Hyg Epidemiol Microbiol Immunol 1987;31:381-9.
81. Mas Lago P, Ramon Bravo J, Andrus JK, et al. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ 1994;72:221-5.
82. Hovi T, Huovilainen A, Kuronen T, et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986; 1:1427-32.
83. Poyry T, Stenvik M, Hovi T. Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl Environ Microbiol 1988;54:371-4.
84. van der Avoort HG, Reimerink JH, Ras A, et al. Isolation of epidemic poliovirus from sewage during the 1992-3 type 3 outbreak in the Netherlands. Epidemiol Infect 1995; 114: 481-91.
85. Richardson G, Linkins RW, Eames MA, et al. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Bull World Health Organ 1995;73:769-77.
86. Conyn van Spaendonck MA, Oostvogel PM, van Loon AM, et al. Circulation of poliovirus during the poliomyelitis outbreak in the Netherlands in 1992-1993. Am J Epidemiol 1996;143:929-35.
87. Andrus J, Aylward B, Hlady G. Vaccine-associated paralytic poliomyelitis (VAPP) - VAPP issues in endemic countries. (Technical consultation on the global eradication of poliomyelitis). Geneva, Switzerland: World Health Organization, 1997. (EPI/POLIO/TECH.97/WP.10).
88. Prevots DR, Ciofi degli Atti ML, Sallabanda A, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis 1998;26:419-25.
89. Black FL. Measles endemicity in insular populations: critical community size and its evolutionary implication. J Theor Biol 1966;11:207-11.
90. Aycock WL, Kessel JF. The infectious period of poliomyelitis and virus detection. Am J Med Sci 1943;205: 454-65.
91. Dietz K. Transmission and control of arbovirus diseases. In: Ludwig D, Cooke KL, eds. Epidemiology. Philadelphia: Society of the Institute of Applied Mathematics, 1975: 104-21.
92. Paul JR, Riordan JT, Melnick JL. Antibodies to three different antigenic types of poliomyelitis virus in sera from North Alaskan Eskimos. Am J Hyg 1951;54:275-85.
93. Paul JR, Melnick JL, Riordan JT. Comparative neutralizing antibody patterns to Lansing (type 2) poliomyelitis virus in different populations. Am J Hyg 1952;56:232-51.
94. Paul JR, Melnick JL, Barnett VH, et al. A survey of neutralizing antibodies to poliomyelitis virus in Cairo, Egypt. Am J Hyg 1952;55:402-13.
95. Melnick JL, Ledinko N. Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period. The ratio of inapparent infection to clinical poliomyelitis. Am J Hyg 1953;58:207-22.
96. Paul JR, Horstmann DM. A survey of poliomyelitis virus antibodies in French Morocco. Am J Trop Med Hyg 1955;4: 512-24.
97. Gelfand HM, Miller MJ. Poliomyelitis in Liberia. Prevalence of the disease, sero-immunity resulting from sub-clinical infection, and indications for prophylactic vaccination. Am J Trop Med Hyg 1956;5:791-6.
98. Coriell LL, Schaeffer K, Felton HM, et al. A serologic and clinical survey of poliomyelitis in Caracas, Venezuela, and Galveston, Texas, and the response to Salk vaccine. Am J Public Health 1956;46:1431-8.
99. Melnick JL. Studies on the serological epidemiology of poliomyelitis as an index in certain Caribbean islands, British Guiana, and Ecuador. West Indian Med J 1959;8:275-98.
100. Fendall NRE. Poliomyelitis in Kenya - the 1960 epidemic and oral vaccine campaign. J Trop Med Hyg 1962;65: 245-55.
101. Wai-Kwan C, Hay S. Poliomyelitis fecal and serological surveys in the Chinese population in Hong Kong in 1960. Am J Trop Med Hyg 1962;11:122-5.
102. Olness KN, Halstead SB, Snitbhan R. Poliomyelitis in Laos, 1962-1963. Epidemic and immunity survey. J Pediatr 1966; 69:316-23.
103. Gust ID, Lewis FA, Lehmann NI. Prevalence of antibody to hepatitis A and polioviruses in an unimmunized urban population. Am J Epidemiol 1978;107:54-6.
104. Schonberger LB, Thaung U, Khi DK, et al. The epidemiology of poliomyelitis in Burma. Dev Biol Stand 1981;47: 283-92.
105. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1992.
106. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265-302.
107. Dietz K. The estimation of the basic reproduction number for infectious diseases. Stat Methods Med Res 1993;2:23-41.
108. Coale AJ, Demeny P. Regional model life tables and stable populations. Princeton, NJ: Princeton University Press, 1966.
109. United Nations. World population prospects: the 1994 revision. New York: United Nations, 1995. (ST/ESA/SER.S/145 and E.95.XIII.16).
110. Eichner M, Hadeler KP, Dietz K. Stochastic models for the eradication of poliomyelitis: minimum population size for polio virus persistence. In: Isham V, Medley G, eds. Models for infectious human diseases: their structure and relation to data. Cambridge: Cambridge University Press, 1996.
111. Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol 1996;143:816-22.
112. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis 1997;175 (suppl 1):S165-72.
113. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol 1979;110:672-92.
114. Gard S, Bottiger M, Lagercrantz R. Vaccination with attenuated poliovirus type 1, the CHAT strain. In: Proceedings of the 1st International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959: 350-4.
115. Paul JR. The spread of attenuated poliovirus among household contacts. (Abstract). In: Poliomyelitis: papers and discussions presented at the 5th International Poliomyelitis Conference, Copenhagen, Denmark, July 26-28, 1960. Philadelphia: JB Lippincott Co, 1960:23-4.
116. Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virol 1961;5:265-73.
117. Schaap GJ, Bijkerk H, Coutinho RA, et al. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol 1984;29: 124-40.
118. Poliomyelitis - United States, 1975-1984. MMWR Morb Mortal Wkly Rep 1986;35:180-2.
119. Isolation of wild poliovirus type 3 among members of a religious community objecting to vaccination - Alberta, Canada, 1993. MMWR Morb Mortal Wkly Rep 1993;42: 337-9.
120. Chin KP, Lok AS, Wong LS, et al. Current seroepidemiology of hepatitis A in Hong Kong. J Med Virol 1991;34:191-3.
121. Wu JS, Lu CF, Wu LZ, et al. Changing seroepidemiology of hepatitis A virus infection between two regions in Taiwan differing in socioeconomic status. J Formos Med Assoc 1993;92:812-15.
122. Kamel MA, Troonen H, Kapprell HP, et al. Seroepidemiology of hepatitis E virus in the Egyptian Nile delta. J Med Virol 1995;47:399-403.
123. Swartz TA, Skalska P, Gerichter CG, et al. Routine administration of oral polio vaccine in a subtropical area. Factors possibly influencing sero-conversion rates. J Hyg Lond 1972;70:719-26.
124. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972;96:263-9.
125. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991;13:926-39.
126. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and The Gambia. J Infect Dis 1995;171:1097-106.
127. Osei Kwasi M, Afari EA, Mimura K, et al. Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana. Bull World Health Organ 1995; 73:41-6.
128. Paul JR, Horstmann DM, Riordan JT, et al. The capacity of live attenuated polioviruses to cause human infection and to spread within families. In: Proceedings of the 2nd International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1960: 174-84.
129. Hale JH, Lee LH, Gardner PS. A study of interference among enteroviruses during the mass immunization campaign with attenuated poliovirus type 2. In: Poliomyelitis: papers and discussions presented at the 5th International Poliomyelitis Conference, Copenhagen, Denmark, July 26-28, 1960. Philadelphia: JB Lippincott Co, 1960:336-41.
130. Voroshilova MK, Zhevandrova VI, Koroleva GA, et al. The effect of enterovirus carriage on results of oral immunization with live poliovirus vaccine from Sabin strains. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:560-73.
131. Drozdov SG, Shirman GA. Interaction of viruses in the intestinal tract of man. I. Interference between wild and vaccine poliovirus strains. Acta Virol 1961;5:210-19.
132. Przesmycki F, Dobrowolska H, Georgiades J, et al. Report on field trials with live attenuated poliomyelitis vaccine of Koprowski in Poland. Am J Hyg 1960;71:275-84.
133. Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 1994;72:973-83.
134. Katz M, Plotkin SA. Minimal infective dose of attenuated poliovirus for man. Am J Public Health 1967;57:1837-40.
135. Verlinde JD, Wilterdink JB. A small-scale trial on vaccination and revaccination with live attenuated polioviruses in the Netherlands. In: Proceedings of the 1st International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959:355-66.
136. Lepow ML, Warren RJ, Gray N, et al. Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants. N Engl J Med 1961;264:1071-8.
137. Henry JL, Jaikaran ES, Davies JR, et al. A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Cambridge) 1966;64:105-20.
138. Alexander JPJ, Gary HEJ, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997;175(suppl 1):S176-82.
139. Melnick JL, Rennick V. Infectivity titers of enterovirus as found in human stools. J Med Virol 1980;5:205-20.
140. Zeitlenok NA, Lovtzevich EL, Bagdasaryan GA. Experimental study of the sensitivity to chlorine of attenuated and virulent poliomyelitis virus strains and their adsorption by various kinds of soil. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:591-4.
141. Reichler MR, Patriarca PA. The place of outbreak response immunization in the control of poliovirus spread. Immunization strategies for poliomyelitis control: preliminary results of a review of the literature from 1900 to the present. (Working paper for the World Health Organization, June 7-11, 1993). Geneva, Switzerland: World Health Organization, 1993. (EPI/TECHCOMM/WP/93.5).
142. Peretz LG, Medvinskaya KG, Neznanskaya II. Interference between different strains of polioviruses in the light of general theory of microbial antagonism. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:580-3.
143. Drosdov SG, Shirman GA, Knyazeva TV. Interference between wild and vaccine strains of poliomyelitis virus in the human intestinal tract. In: Choumakov MP, ed. Oral live poliovirus vaccine. (Papers presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, May 17-20, 1960). Moscow: Academy of Medical Sciences of the USSR, 1961:546-59.
144. Ramsay ME, Begg NT, Gandhi J, et al. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 1994;13:1117-21.
145. De Quadros CA, Andrus JK, Olive JM, et al. Polio eradication from the Western hemisphere. Annu Rev Public Health 1991;13:239-53.
146. Cossart YE. Evolution of poliovirus since introduction of attenuated vaccine. Br Med J 1977;1:1621-3.
147. Sellwood J, Dadswell JV, Slade JS. Viruses in sewage as an indicator of their presence in the community. J Hyg Lond 1981;86:217-25.
148. Macdonald G. The epidemiology and control of malaria. London: Oxford University Press, 1957.
149. World Health Organization. EPI information system. Global summary August, 1997. Geneva, Switzerland: World Health Organization, 1997. (WHO/EPI/GEN/97.02).
150. Cohen Abbo A, Culley BS, Reed GW, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatr Infect Dis J 1995;14:100-6.
151. Nishio O, Ishihara Y, Sakae K, et al. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand 1984;12:1-10.
152. Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6.
153. Glezen WP, McCollough RH, Lamb GA, et al. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol 1969;90: 146-56.
154. Smith JW, Lee JA, Fletcher WB, et al. The response to oral poliovaccine in persons aged 16-18 years. J Hyg Lond 1976; 76:235-47.
155. Holguin AH, Reeves JS, Gelfand HM. Immunization of infants with the Sabin oral poliovirus vaccine. Am J Public Health 1962;52:600-10.
156. Bottiger M. A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 1987;19:595-601.
157. Black FL, Hierholzer WJ, Pinheiro F, et al. Evidence for persistence of infectious agents in isolated human populations. Am J Epidemiol 1974;100:230-50.
158. Parkman P. An assessment of the safety and efficacy implications of removing the type 2 strain from the trivalent oral poliovirus vaccine. Presented at the Stopping Polio Immunization Meeting of the World Health Organization, Geneva, Switzerland, March 31, 1997.
159. Cochi SL, Sutter RW, Kew OM, et al. A decision tree for stopping polio immunization. Technical consultation on the global eradication of poliomyelitis. Geneva, Switzerland: World Health Organization, 1997. (EPI/POLIO/TECH.97/WP.18).